Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.

This article summarizes the recent literature in (18)F-fluorodeoxyglucose/positron emission tomography (FDG-PET) imaging of head and neck cancers and extends the previous review in this area by Schöder and Yeung in the July 2004 issue of Seminars in Nuclear Medicine. Positron emission tomography/computed tomography (PET-CT) imaging is now used widely but has not been adequately evaluated for head and neck cancer. Its accuracy in initial staging is better than CT but may be similar to magnetic resonance imaging. It is not sufficiently accurate in the N0 neck to rule out nodal metastases but may be appropriate if sentinel node mapping is performed in patients with PET studies showing no nodal disease. PET imaging is beginning to be used in radiotherapy treatment planning, where it makes a significant difference by identifying malignant normal size nodes, extent of viable tumor, and distant disease. PET continues to be useful in carcinoma of unknown primary in identification of the primary site. Overall success is around 27% after all other modalities have failed. FDG-PET is being used frequently to assess response to therapy and for surveillance thereafter. The major controversy is when to image after radiotherapy or combined chemo-radiotherapy. One month seems to be too early. The ideal time seems to be 3 to 4 months to avoid both false-positive and false-negative studies. The growing use of PET-CT studies in head and neck cancer will certainly make a significant difference in the treatment and outcome in this disease.

[1]  C. Grau,et al.  Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Cyrill Burger,et al.  Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. , 2003, International journal of radiation oncology, biology, physics.

[3]  A. Lammertsma,et al.  The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[4]  David Schuster,et al.  Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. , 2005, International journal of radiation oncology, biology, physics.

[5]  E. Rosenthal,et al.  Positron emission tomography in the evaluation of stage III and IV head and neck cancer , 2001, Head & neck.

[6]  U. Pietrzyk,et al.  2[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is a Sensitive Tool for the Detection of Occult Primary Cancer (Carcinoma of Unknown Primary Syndrome) with Head and Neck Lymph Node Manifestation , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[7]  J. Kaanders,et al.  Value of routine follow‐up for patients cured of laryngeal carcinoma , 2004, Cancer.

[8]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[9]  G. V. von Schulthess,et al.  Positron emission tomography in the early follow-up of advanced head and neck cancer. , 2004, Archives of otolaryngology--head & neck surgery.

[10]  F. Civantos,et al.  Sentinel node biopsy in oral cavity cancer: Correlation with PET scan and immunohistochemistry , 2003, Head & neck.

[11]  J. Debatin,et al.  Unknown primary tumors: detection with dual-modality PET/CT--initial experience. , 2005, Radiology.

[12]  Yoshimi Anzai,et al.  FDG‐PET/CT–guided intensity modulated head and neck radiotherapy: A pilot investigation , 2005, Head & neck.

[13]  J. Johansen,et al.  Implication of 18F‐Fluoro‐2‐Deoxy‐D‐Glucose Positron Emission Tomography on Management of Carcinoma of Unknown Primary in the Head and Neck: A Danish Cohort Study , 2002, The Laryngoscope.

[14]  K. Geisinger,et al.  Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? , 2002, International journal of radiation oncology, biology, physics.

[15]  H. Schöder,et al.  Positron emission imaging of head and neck cancer, including thyroid carcinoma. , 2004, Seminars in nuclear medicine.

[16]  Peter A S Johnstone,et al.  FDG-PET in radiotherapy treatment planning: Pandora's box? , 2004, International journal of radiation oncology, biology, physics.

[17]  Dean Billheimer,et al.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  T. Klenzner,et al.  Lymph node staging in extracranial head and neck cancer with FDG PET – appropriate uptake period and size-dependence of the results , 2002, Nuklearmedizin.

[19]  Roland Bares,et al.  Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. , 2005, AJR. American journal of roentgenology.

[20]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[21]  G. V. von Schulthess,et al.  Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. , 2003, Oral oncology.

[22]  S. Stoeckli,et al.  Is there a role for positron emission tomography with 18F‐fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma , 2002, Head & neck.

[23]  H. Steinert,et al.  Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  W. Waddington,et al.  A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. , 2003, Oral oncology.

[25]  J. Buatti,et al.  Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. , 2004, International journal of radiation oncology, biology, physics.

[26]  L. Peters,et al.  The usefulness of fluorine 18–labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor , 2003, Head & neck.

[27]  Tohru Shiga,et al.  Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. , 2002, International journal of radiation oncology, biology, physics.

[28]  S. Stringer,et al.  Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. , 2001, American journal of otolaryngology.

[29]  K. Greven,et al.  Occult primary tumors of the head and neck , 1999, Cancer.

[30]  J. Eary,et al.  Staging of head and neck squamous cell cancer with extended-field FDG-PET. , 2003, Archives of otolaryngology--head & neck surgery.

[31]  Jin-Sook Ryu,et al.  Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET. , 2005, Oral oncology.

[32]  Dwight E Heron,et al.  Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. , 2004, International journal of radiation oncology, biology, physics.

[33]  S. Stringer,et al.  SQUAMOUS CELL CARCINOMA METASTATIC TO CERVICAL LYMPH NODES FROM AN UNKNOWN HEAD AND NECK PRIMARY SITE , 1998 .

[34]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[35]  W. Wong,et al.  The impact of FDG PET on the management of occult primary head and neck tumours. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[36]  J. Gaa,et al.  Positron emission tomography in combination with sentinel node biopsy reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Visvikis,et al.  Impact of combined 18F-FDG PET/CT in head and neck tumours , 2005, British Journal of Cancer.

[38]  Kyle E. Rusthoven,et al.  The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor , 2004, Cancer.

[39]  P. Mikosch,et al.  Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods , 2001, European Journal of Nuclear Medicine.

[40]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[41]  J. Buatti,et al.  The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[42]  Yoshimi Anzai,et al.  FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[43]  J. Shah,et al.  The role of neck dissection following definitive chemoradiation. , 2004, Oncology.